Executive takeaways
  • Flexibility is a prepared capability, not permission to improvise.
  • The commercial value comes from reducing response time before disruption occurs.
  • Every acceptable change needs evidence, traceability and a clearly owned decision.
  • Claims on the label must remain aligned with the formulation actually produced.

A flexible formulation portfolio can widen sourcing options, protect service levels and make a lubricant business more resilient. But the word “flexible” is easily misunderstood. It should describe the strength of the preparation around a product—not a lower threshold for technical discipline.

Flexibility starts before the shortage

Our analysis: the commercial advantage is created months before a constrained component becomes urgent. Businesses that know their approved alternatives, evidence gaps, test capacity and decision rights can act while competitors are still trying to assemble the facts.

A practical readiness review asks:

  • Which products depend on one source, one geography or one narrow interchange position?
  • Where has an alternative already been reviewed by the additive technology provider?
  • Which changes would affect licences, OEM approvals, customer registrations or safety documentation?
  • How quickly can the organisation manufacture, segregate, trace and release an approved alternative?
  • Which high-volume products justify proactive testing of a second path?

This work is not only technical. It requires procurement visibility, commercial prioritisation, quality-system ownership and a financial view of qualification cost versus continuity value.

A claim is a controlled system

What is established: API’s Engine Oil Licensing and Certification System governs the use of API engine-oil quality marks. ACEA publishes oil sequences that define performance requirements used in European engine-oil claims. OEM licensing and approval systems may add further conditions.

Those frameworks are not interchangeable. A product can sit within several overlapping evidence systems: an industry sequence, a licensor’s rules, an additive-package programme, an OEM approval, customer-specific requirements and internal quality controls. A change needs to be assessed against the systems that actually support the marketed claim.

Build a disciplined change dossier

When a change is proposed, the decision should not live across scattered emails. A concise change dossier can include:

  1. Reason: the constraint or opportunity and the products affected.
  2. Technical position: formulation comparison, supplier guidance, applicable interchange or read-across basis and identified limitations.
  3. Claim review: API, ACEA, OEM, contractual and label implications.
  4. Evidence plan: testing, documentation, approval and release requirements.
  5. Operational control: material identity, tank and line management, batch traceability, certificates and transition timing.
  6. Customer plan: whether notification, approval, revised documentation or a different product recommendation is required.
  7. Decision record: accountable approvers, scope, expiry or review date.

The dossier need not be bureaucratic. It needs to be complete enough that another qualified person can understand the basis of the decision after the urgency has passed.

Do not confuse chemical plausibility with permission

An alternative base stock may look plausible by viscosity, volatility, saturates or sulphur. An additive component may appear functionally similar. That is the beginning of a question, not the end of the decision. Interaction effects, treat rates, seal compatibility, oxidation behaviour, low-temperature performance, catalyst compatibility and claim-specific rules can matter.

The relevant technology provider and current primary documents should guide what can be read across, what must be tested and what cannot be claimed. Where a licensor offers case-specific relief, as ILMA reported in relation to GM dexos requests during the 2026 disruption, obtain the written position for the specific product and situation.

Prepared flexibility makes good decisions faster. Uncontrolled flexibility only makes risk move faster.

Measure the capability, not only the outcome

A team may avoid a stock-out through extraordinary effort and still have a fragile system. Better indicators look upstream:

  • share of priority volume with a documented alternative supply path;
  • time needed to assemble a complete change dossier;
  • number of products with unresolved claim or documentation dependencies;
  • qualification capacity and average cycle time by risk level;
  • percentage of emergency changes closed with full post-event review.

These measures show whether flexibility is becoming repeatable. They also help management decide where a qualification programme can create more value than another short-term negotiation.

The commercial payoff

Responsible formulation flexibility can protect revenue, reduce forced product rationalisation and improve customer confidence. It can also make supplier conversations more strategic because the business understands which dependencies are critical and which are choices.

The capability belongs across functions. Technical teams establish the evidence. Quality protects the control system. Operations preserve identity and traceability. Procurement creates viable options. Commercial teams set priorities and communicate honestly. Leadership makes sure that time pressure never changes the standard of proof.